Actively Recruiting
Phase 2 Study Comparing Tedizolid, Linezolid, and Standard Quadruple Therapy for Early Bactericidal Activity in Pulmonary Tuberculosis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-02-03
60
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the early bactericidal activity of tedizolid in patients with pulmonary tuberculosis caused by Mycobacterium tuberculosis. This Phase 2, randomized, open-label trial compares tedizolid to linezolid and the standard quadruple therapy used for drug-susceptible tuberculosis. The goal is to evaluate how quickly these treatments kill bacteria early in the course of therapy. Participants are randomly assigned to one of three groups tedizolid 200 mg once daily for 7 days, linezolid 600 mg twice daily for 7 days, or the standard quadruple therapy consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide given once daily for 7 days. Each drug or combination is taken in the morning, with tedizolid and linezolid allowed with or without meals, while the quadruple therapy is taken on an empty stomach. During the study, sputum samples are collected daily for 7 days to measure bactericidal activity. Participants have blood tests and consultations at day 30 to assess safety and tolerance, including monitoring of blood counts and liver and kidney function. The primary outcome is the early bactericidal activity of tedizolid after the first 2 days of treatment, with further evaluations performed up to day 8. The total participation lasts about one month, including treatment and follow-up assessments.
CONDITIONS
Brief Title
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
Research Team
N
Nicolas VEZIRIS, PU-PH
R
Ruxandra CALIN, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here